CytoCare is claimed to be the world’s first and only automated robotic system for the safe preparation of hazardous patient-specific IV medications. Originally developed for cancer therapy, CytoCare has also been proven to compound monoclonal antibodies therapy IV admixtures to treat patients with Crohn’s disease, organ transplants, multiple sclerosis, rheumatoid arthritis, and infectious diseases, said Health Robotics.
DIG will initially staff its Health Robotics product team at its Beijing and Shanghai office locations, in addition to planned local manufacturing operations.
John Bennett, CEO of Devon International Group, said: “While CytoCare remedies the considerable Chinese-specific problem of retention of child-bearing-age clinicians due to the hazardous nature of chemo IVs, iv Station solves the IV sterility issues associated with compounding at non-sterile patient care locations.
“We look forward to officially launch both Health Robotics’s solutions at the China International Medical Equipment Fair in Shenzhen on April 18-21, 2009.”